Avance Trials — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$16,439	4
2024	Research	$38,431	4
2023	Research	$148,587	11
2022	Research	$82,297	9
2021	Research	$52,166	12

Breakdown

Who paid Research payments · program years 2021–2025

Eli Lilly and Company $311,514 19 payments
Acrotech Biopharma LLC $21,261 5 payments
Sun Pharmaceutical Industries Inc. $5,145 16 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $101,628 2 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $77,789 4 payments
An Open-Label 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color $64,211 2 payments
An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab $25,304 2 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $21,757 1 payment
246-13651-302 $21,261 5 payments
A Phase 3 16-Week Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $16,054 1 payment
Efficacy and Safety Study of ILUMYA in the Treatment of Nail Psoriasis $4,515 11 payments
An Open-Label, Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab $1,956 3 payments
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $1,777 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.